André Mercanzini, PhD, CEO and Co-Founder
His doctoral thesis on the in vivo application of neurological implants formed Alevaʼs core technology. He gained product development experience at MIT Artificial Intelligence Laboratory, Zyvex Corporation (TX, USA) and Bosch Research (Silicon Valley, USA). He holds over 10 international patent families on neuromodulation and microassembly of medical devices. André obtained his BS in Engineering Physics from the University of Toronto, MS in Management Science from Stanford University, and PhD in Biomedical Engineering from the EPFL, Switzerland.
Alain Jordan, MSc, COO
Alain has more than 20 years of experience in development and manufacturing of active implantable devices. As first employee of Endoart SA, he was playing a key role in all aspects of project and technology management. He has thorough knowledge of EU and US requirements relative to development and production of active implantable devices.
After the acquisition of Endoart SA by Allergan Inc., he was leading a multidisciplinary team of 28 people involved in development and manufacturing of active implantable devices. Alain obtained his MS in Microengineering from EPFL, and his Postgraduate Degree in Biomedical Engineering from EPFL, Lausanne University and Geneva University, Switzerland.
Alain Dransart, MSc, Clinical and Regulatory Affairs Director
Alain has extensive experience in medical devices, first with Haemonetics Corporation (automated blood separation), then with Medtronic Europe (pacemakers and heart valves), and most recently as a consultant in Product Management, Market Analysis and Clinical Management. He has led clinical validation of new products, market research, and product launch in Europe. Alain obtained his MS in Electrical Engineering from EPFL, and followed the PED management program at IMD, Switzerland.
BOARD OF DIRECTORS
Dr. Markus Hosang, PhD,
Markus Hosang is a General Partner and a Managing Director at BioMedPartners AG in Basel. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical and diagnostics research and in many product development and marketing areas. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European investment activities. Previously, he was a Vice President at Roche in Basel, where he held several senior management positions of increasing importance in the Pharma R&D organization.
Dr. Hosang currently is a member of the boards of Aleva Neurotherapeutics SA, Ayoxxa Biosystems GmbH, Cardior Pharmaceuticals GmbH, Imevax GmbH, ImmunOs AG and Vaximm AG. Earlier he was on the boards of Omrix AG, Kourion AG, IDEA AG, Atugen GmbH, Avontec GmbH, Neuraxo GmbH, Anergis SA, Affimed AG, Evolva AG, Okairos AG, GenKyoTex SA, Suppremol GmbH and Hookipa Pharma Inc.
Patrick Aisher is a serial entrepreneur who has invested in the life science industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services in over 50 direct investments. Aisher’s portfolio includes over a dozen successful IPO’s and trade exits.
Aisher is Chairman of Kinled Holding, a Hong Kong-based private investment company established in 1924, with offices in London, Shanghai, Vienna, and Zurich. Kinled holds a portfolio of more than 100 companies in the life sciences, digital and financial technology industries. He is a Founder/Partner in five independently-managed funds and is a member of the Swiss Corporate Finance and Private Equity Association.
He has invested in early stage medical spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva.
A strong advocate of seed funding academic research into innovative business concepts, Patrick is also a Director of the Central European Biotechnology Incubator Accelerator at the University of Vienna’s BioCampus, and CEBINA Bridge Capital Limited, a Gibraltar company established as a private scheme within the meaning of the Financial Services Act 2019, under the EU AIFMD regulations.
Annette Franqui is a seasoned business executive with close to 30 years of experience in the financial industry.
She is one of the founding partners of Forrestal Capital, a business and financial advisory firm formed in 2003 to counsel a number of Latin American families. Annette is a member of the board of directors of NYSE listed Arcos Dorados and of various privately held entities. As a volunteer, she is a member of the national board of directors of AARP, one of the largest nonprofit organizations in the United States. Annette received a BSE from the Wharton School and an MBA from Stanford University.
Dr. Robert Watson, PhD
Rob is a co-founder and managing partner of Gyrus Capital, a healthcare-focused private equity firmed based in Geneva, Switzerland. Before investing Rob was a neuroscientist and has published research into neurodegenerative diseases. He has an MBiochem in Biochemistry and a DPhil in Neurology from the University of Oxford.
André Mercanzini, PhD
Jean-Pierre Rosat, PhD, MBA
With extensive experience in creating and developing high tech companies, Jean-Pierre has co-founded more than eight start-ups, made three trade-sales to public companies, and is well-versed in fund-raising and setting-up new projects. He has been previously CEO of Cytion SA, Apoxis SA and picoDrill SA. Jean-Pierre gained experienced with FDA and EMEA regulation while developing oncology drugs, and combines this experience with engineering ventures that focused on automated drug screening equipment and micro-machining technology.
Prof. Claudio Pollo, MD, PD&MER, FMH - Head of Functional Neurosurgery, Inselspital, Bern
Known for his innovative work in applying DBS to movement disorders, epilepsy, pain and psychiatric disorders, he has treated close to 200 patients using DBS surgery. He studied Neurosurgery under the inventor of DBS therapy, Dr. Alim Benabid in Grenoble, France. He is a co-inventor of microDBSTM technology and is Principal Investigator for Alevaʼs first-in-man studies.
Prof. Philippe Renaud, PhD, Professor EPFL
Philippe Renaud is Professor at the Microsystem Laboratory at EPFL. He is also the scientific director of the EPFL Center of MicroNanoTechnology (CMI). His main research area is related to micro and nano-technologies in biomedical applications (BioMEMS) with emphasis on cell-chips, nanofluidics and bioelectronics. Ph. Renaud is involved in many scientific papers in his research area. More than 13 successful start-ups have been created out of research conducted in his laboratory.
Paul, a co-founder of Aleva, assists the company with strategy, business development and US operations. He has been an executive at two MIT start-ups (NetBio Inc. and Boston Microsystems, recently acquired by Pall Corporation) and was a vice-president and executive officer at Ansoft Corporation (NASDAQ:ANST, acquired by ANSYS). Paul is currently CEO of Sakti Medical Systems, a U.S.-based healthcare company focused on improving outcomes for patients suffering from chronic pain and addictive disorders. He obtained his BSEE from Carnegie-Mellon and MBA from IMD.
Prof. Andres Lozano, MD, PhD
Andres is currently Professor in the Department of Surgery, and inaugural Chair Holder of the Ron Tasker Chair in Stereotactic and Functional Neurosurgery at the University Health Network. His main research and clinical interests lie in the field of the neurosurgical treatment of movement disorders and micro-electrode recordings of the human brain.
Prof. Philippe Renaud, PhD